(Q38140308)

29 August 2017

Urine markers for detection and surveillance of bladder cancer (English)

1 reference

29 August 2017

5

Yair Lotan

1 reference

29 August 2017

4

Pierre I Karakiewicz

1 reference

29 August 2017

6

Shahrokh F Shariat

1 reference

29 August 2017

2

Luis A Kluth

1 reference

29 August 2017

1

Evanguelos Xylinas

1 reference

29 August 2017

3

Malte Rieken

1 reference

PubMed ID

24054865

29 August 2017

language of work or name

1 reference

17 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

32

1 reference

29 August 2017

222-229

1 reference

29 August 2017

3

1 reference

29 August 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Economic aspects of bladder cancer: what are the benefits and costs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Epidemiology and risk factors of urothelial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Screening for bladder cancer: a perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Statistical consideration for clinical biomarker research in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Words of wisdom. Re: Rethinking screening for breast cancer and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Early results of bladder-cancer screening in a high-risk population of heavy smokers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Screening for bladder cancer: rationale, limitations, whom to target, and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Bladder cancer markers in patient management: the current perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Detection of bladder cancer using a point-of-care proteomic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Improved detection of recurrent bladder cancer using the Bard BTA stat Test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Urine based markers of urological malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Noninvasive detection of bladder cancer with the BTA stat test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Comparison of screening methods in the detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Utility of the BTA stat test kit for bladder cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

HUMAN COMPLEMENT FACTOR H RELATED PROTEIN TEST FOR MONITORING BLADDER CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Qualitative and Quantitative Detection of Urinary Human Complement Factor H-Related Protein (BTA stat and BTA TRAK) and Fragments of Cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as Markers for Transitional Cell Carcinoma of the Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

A side by side comparison of cytology and biomarkers for bladder cancer detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Tumor markers in the diagnosis of primary bladder cancer. A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Urine markers for bladder cancer surveillance: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Bladder cancer detection with urinary survivin, an inhibitor of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Survivin: a promising biomarker for detection and prognosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Clinical experience with survivin as a biomarker for urothelial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Use of the novel marker BLCA-1 for the detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Highly specific urine-based marker of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Functional characterization of the bladder cancer marker, BLCA-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.06.001

10.1016/J.UROLONC.2013.06.001

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

24054865